In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Spero Therapeutics Inc (SPRO), with a price target of $27. The company’s shares opened today at $11.38.
Chen commented:
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $27 for SPRO shares. As the company advances its pipeline toward commercialization, we think upward earnings revisions and multiple expansion to levels not reflected in FactSet consensus expectations will drive SPRO’s stock higher. We also like the stock ahead of what we expect to be multiple positive data readouts for 2019+. Anticipated 2019 events include pharmacokinetic data from a lead-in cohort of 70 patients in 2H19 for SPR994 in the cUTI patient population, Phase 1 data for 1 data for SPR720.”
According to TipRanks.com, Chen is a 4-star analyst with an average return of 7.4% and a 40.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries Limited, Bausch Health Companies Inc, and Amneal Pharmaceuticals Inc.
Currently, the analyst consensus on Spero Therapeutics Inc is a Moderate Buy with an average price target of $27.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.23 and a one-year low of $5.52. Currently, Spero Therapeutics Inc has an average volume of 81.02K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206.
